oversold, page-103

Perhaps this is the main reason why Resmed has made those recent acquisitions. To be a market leader in COPD and strives for more innovative technology to treat chronic respiratory disease, not just sleep apnea. 

The opportunity is HUGE!!!

Global Respiratory Devices Market to Surpass US$ 35 Billion by 2026
https://www.marketwatch.com/press-release/global-respiratory-devices-market-to-surpass-us-35-billion-by-2026-2019-01-30

Furthermore, some encouragement for those willing to ride long term with RMD. 
https://investorplace.com/2019/01/the-10-best-stocks-to-buy-for-the-next-decade/
Who knew that sleep apnea paid so well?
ResMed Inc. (NYSE:RMD) manufactures medical devices and provides cloud-based software applications for medical professionals to treat and manage sleep apnea and chronic obstructive pulmonary disease (COPD). Treating 2 million patients daily, ResMed has become good at reducing healthcare costs by minimizing the effects of chronic disease.Good businesses make and save people and companies money. ResMed does both.Over the past decade, ResMed has delivered an annual return to shareholders of 16.98%, much greater than the S&P 500.According to a recent study, 26% of adults have sleep apnea — a disorder that can wreak havoc on a person’s heart, not to mention a marriage due to both partners’ lack of sleep. My dad died as a result of COPD, a disease that affects more than 200 million people worldwide and costs the healthcare system more than $50 billion per year in the U.S. alone. ResMed has growth opportunities in Latin America, Eastern Europe and China and India — all huge markets that will keep it busy for the next decade and beyond.Of all the stocks to buy for the next decade, ResMed is my pick for most reliable given the markets it serves.